Published in Catheter Cardiovasc Interv on November 15, 2008
Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: Propensity score analysis. Catheter Cardiovasc Interv (2008) 1.79
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation (2002) 4.99
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38
Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. Catheter Cardiovasc Interv (2010) 3.24
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol (2003) 3.13
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med (2004) 3.07
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05
Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation (2003) 2.77
Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol (2013) 2.64
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted meta-analysis of 18,061 patients from 65 studies. JACC Cardiovasc Interv (2013) 2.54
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J (2004) 2.42
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol (2008) 2.38
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J (2004) 2.29
Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS). Circulation (2003) 2.21
Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation (2004) 2.21
Frequency and risk of noncardiac surgery after drug-eluting stent implantation. Catheter Cardiovasc Interv (2011) 2.18
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol (2003) 2.17
Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA (2007) 2.10
Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med (2012) 2.09
The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol (2002) 2.03
Impact of prior coronary artery bypass graft surgery on chronic total occlusion revascularisation: insights from a multicentre US registry. Heart (2013) 1.89
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76
Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J (2006) 1.73
Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. J Am Coll Cardiol (2013) 1.72
Saphenous vein graft intervention. JACC Cardiovasc Interv (2011) 1.69
Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). JACC Cardiovasc Interv (2010) 1.67
The efficacy of "hybrid" percutaneous coronary intervention in chronic total occlusions caused by in-stent restenosis: insights from a US multicenter registry. Catheter Cardiovasc Interv (2014) 1.64
Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol (2004) 1.64
Readmission in the 30 days after percutaneous coronary intervention. JACC Cardiovasc Interv (2013) 1.63
Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol (2002) 1.62
Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res (2006) 1.61
Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J (2004) 1.60
Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood (2002) 1.59
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv (2011) 1.56
Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. Circulation (2006) 1.55
Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J (2010) 1.55
Frequency and outcomes of aortocoronary dissection during percutaneous coronary intervention of chronic total occlusions: a case series and systematic review of the literature. Catheter Cardiovasc Interv (2013) 1.53
Use of drug-eluting stents for chronic total occlusions: a systematic review and meta-analysis. Catheter Cardiovasc Interv (2011) 1.51
Temporal trends of fluoroscopy time and contrast utilization in coronary chronic total occlusion revascularization: insights from a multicenter united states registry. Catheter Cardiovasc Interv (2014) 1.48
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J (2011) 1.47
Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. Am Heart J (2004) 1.47
One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. EuroIntervention (2013) 1.47
Treatment of the chronic total occlusion: a call to action for the interventional community. Catheter Cardiovasc Interv (2014) 1.46
The New York State risk score for predicting in-hospital/30-day mortality following percutaneous coronary intervention. JACC Cardiovasc Interv (2013) 1.45
Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med (2003) 1.44
Prevalence and management of coronary chronic total occlusions in a tertiary Veterans Affairs hospital. Catheter Cardiovasc Interv (2013) 1.44
Pilot trial of cryoplasty or conventional balloon post-dilation of nitinol stents for revascularization of peripheral arterial segments: the COBRA trial. J Am Coll Cardiol (2012) 1.43
Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial. Circ Cardiovasc Qual Outcomes (2009) 1.43
Incidence, correlates, management, and clinical outcome of coronary perforation: analysis of 16,298 procedures. Am Heart J (2004) 1.43
Percutaneous intervention of acutely occluded saphenous vein grafts: contemporary techniques and outcomes. J Invasive Cardiol (2010) 1.43
ST-elevation myocardial infarction patients can be enrolled in randomized trials before emergent coronary intervention without sacrificing door-to-balloon time. Am Heart J (2009) 1.42
Embolic capture angioplasty in peripheral artery interventions. J Endovasc Ther (2012) 1.42
Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol (2012) 1.42
Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J (2003) 1.41
Intercatheter reproducibility of near-infrared spectroscopy for the in vivo detection of coronary lipid core plaques. Catheter Cardiovasc Interv (2011) 1.40
Impact of a Disposable Sterile Radiation Shield on Operator Radiation Exposure During Percutaneous Coronary Intervention of Chronic Total Occlusions. J Invasive Cardiol (2015) 1.40
Adoption of the hybrid CTO approach by a single non-CTO operator: procedural and clinical outcomes. J Invasive Cardiol (2015) 1.40
Impact of Chronic Total Occlusions on Revascularization Scores and Outcome Prediction. J Invasive Cardiol (2017) 1.40
Percutaneous coronary intervention for ST-segment and non-ST-segment elevation myocardial infarction at hospitals with and without on-site cardiac surgical capability. Mayo Clin Proc (2004) 1.40
Outcomes of preoperative bridging therapy for patients undergoing surgery after coronary stent implantation: a weighted meta-analysis of 280 patients from eight studies. Catheter Cardiovasc Interv (2014) 1.40
Systems of care for ST-segment-elevation myocardial infarction: a report From the American Heart Association's Mission: Lifeline. Circ Cardiovasc Qual Outcomes (2012) 1.39
Comparison of procedural complications and in-hospital clinical outcomes between patients with successful and failed percutaneous intervention of coronary chronic total occlusions: a meta-analysis of observational studies. Catheter Cardiovasc Interv (2014) 1.39
Safety and efficacy of cutting balloon angioplasty: the Mayo Clinic experience. J Invasive Cardiol (2002) 1.39
The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy. Urology (2013) 1.39
Applications of the distal anchoring technique in coronary and peripheral interventions. J Invasive Cardiol (2011) 1.38
In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry. Catheter Cardiovasc Interv (2012) 1.38
Magnetic navigation facilitates percutaneous coronary intervention for complex lesions. Catheter Cardiovasc Interv (2013) 1.38
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med (2008) 1.37
Relationship of walking impairment and ankle-brachial index assessments with peripheral arterial translesional pressure gradients. J Invasive Cardiol (2011) 1.37
Use of a novel crossing and re-entry system in coronary chronic total occlusions that have failed standard crossing techniques: results of the FAST-CTOs (Facilitated Antegrade Steering Technique in Chronic Total Occlusions) trial. JACC Cardiovasc Interv (2012) 1.35
Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. Circulation (2005) 1.30
Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation (2003) 1.27
Perioperative management of patients with coronary stents. J Am Coll Cardiol (2007) 1.25
In vivo characterization of coronary plaques: novel findings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy. Eur Heart J (2011) 1.24
Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. J Am Coll Cardiol (2011) 1.23
Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2013) 1.21
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med (2011) 1.20